Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network
European Journal of Cancer2019Vol. 117, pp. 121–130
Citations Over TimeTop 1% of 2019 papers
Carole Soussain, Sylvain Choquet, Marie Blonski, Delphine Leclercq, Caroline Houillier, Keyvan Rezaï, Fontanet Bijou, Roch Houot, E. Boyle, Rémy Gressin, Emmanuelle Nicolas‐Virelizier, Maryline Barrié, Cécile Moluçon‐Chabrot, M.L. Lelez, Aline Clavert, Solène Coisy, Stéphanie Leruez, Valérie Touitou, Nathalie Cassoux, Maïlys Daniau, Marjan Ertault de la Bretonnière, Abderrazak El Yamani, Hervé Ghesquières, Khê Hoang‐Xuan
Related Papers
- → Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia(2021)12 cited
- → Ibrutinib Use Complicated by Progressive Multifocal Leukoencephalopathy(2018)11 cited
- → Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions(2021)6 cited
- → A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome(2021)3 cited
- → Use of Ibrutinib for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice: Results from the Belgian Ibrutinib Real-World Data (BiRD) Study(2018)1 cited